Drug-suicide link complex, data elusive

Is it possible to draw a straight line between patient suicide and prescription drugs? It's a touchy subject. Within the last few weeks, the FDA alerted the public that epilepsy drugs appear to boost the remote risk of suicide (or at least suicidal thoughts), that Pfizer's stop-smoking drug Chantix may do the same, and that it's requiring more suicide-related data in drug trials. Is suicide the scary drug risk du jour? Or is the explosion activity long overdue?

The New York Times examines the question today and basically concludes that clarity will be elusive. Unless, that is, lawmakers mandate massive databases of patient-and-drug info designed to sift out rare side effects.

- check out the NYT's release

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.